Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 8
5-HTP efficacy and contraindications
Authors Hinz M, Stein A, Uncini T
Received 24 April 2012
Accepted for publication 14 May 2012
Published 19 July 2012 Volume 2012:8 Pages 323—328
DOI https://doi.org/10.2147/NDT.S33259
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
This paper has been retracted.
Marty Hinz, 1 Alvin Stein, 2 Thomas Uncini 3
1Clinical Research, NeuroResearch Clinics, Inc, Cape Coral, 2Stein Orthopedic Associates, Plantation, FL, USA; 3University Medical Center Mesabi Hibbing, MN, USA
Abstract: L-5-hydroxytryptophan (5-HTP) is the immediate precursor of serotonin. It is readily synthesized into serotonin without biochemical feedback. This nutrient has a large and strong following who advocate exaggerated and inaccurate claims relating to its effectiveness in the treatment of depression and a number of other serotonin-related diseases. These assertions are not supported by the science. Under close examination, 5-HTP may be contraindicated for depression in some of the very patients for whom promoters of 5-HTP advocate its use.
Keywords: 5-HTP, 5-hydroxytryptophan, L-5-HTP, L-5-hydroxytryptophan
Expression of Concern for this paper has been published
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.